



Reinhard Dummer

Contact

Reinhard Dummer

Publications (62)

Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova-Hötzenecker E, Gniadecki R, Hodak E, Jonak C, Klemke C, Knobler R, Morris S, Nicolay J, Ortiz-Romero P, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer M, Wehkamp U, Whittaker S, Willemze R, Trautinger F. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. *Eur J Cancer* 2023; 195:113343.

Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. *J Am Acad Dermatol* 2023; 89:1072-1074.

Troesch A, Hoellwerth M, Forchhammer S, Del Regno L, Lodde G, Turko P, Cheng F, Levesque M, Hadaschik E, Livingstone E, Peris K, Flatz L, Koelblinger P, Dummer R, Dimitriou F. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. *J Eur Acad Dermatol Venereol* 2023; 37:922-931.

Ramelyte E, Nägeli M, Hunger R, Merat R, Gaide O, Navarini A, Cozzio A, Wagner N, Maul L, Dummer R. Swiss Recommendations for Cutaneous Basal Cell Carcinoma. *Dermatology* 2022; 239:1-10.

Voglis S, Schaller V, Müller T, Gönel M, Winklhofer S, Mangana J, Dummer R, Serra C, Weller M, Regli L, Le Rhun E, Neidert M. Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival. *Eur J Cancer* 2022; 175:158-168.

Kostner L, Cerminara S, Pamplona G, Maul J, Dummer R, Ramelyte E, Mangana J, Wagner N, Cozzio A, Kreiter S, Kogler A, Streit M, Wysocki A, Zippelius A, Läubli H, Navarini A, Maul L. Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. *Cancers (Basel)* 2022; 14

Zehnder M, Amarov B, Abrunhosa-Branquinho A, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini A, Cozzio A, Dummer R, Dimitriou F, Guenova E. Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. *Dermatology* 2022; 238:967-976.

Maredia H, Cozzio A, Dummer R, Ramelyte E, Kim E, Rozati S. Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome. *JAAD Case Rep* 2021; 15:92-96.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuvecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebahr S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:280.

Dimitriou F, Cozzio A, Dummer R, French L, Hoetzenecker W, Brügggen M, Kimeswenger S, Nair G, Schanz U, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. *Front Med (Lausanne)* 2020; 7:290.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuvecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebahr S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:135.

Saulite I, Bobrowicz M, Hoetzenecker W, Pascolo S, Scarisbrick J, Dummer R, Cozzio A, Nägeli M, Anzengruber F, Varypataki E, Dimitriou F, Fassnacht C, Chang Y, Desislava I, Guenova E. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. *Oncoimmunology* 2020; 9:1738797.

Brüggen M, Schlaak M, Nguyen V, Romani N, Cozzio A, Nair G, Dimitriou F, French L, Dummer R, Guenova E, Wehkamp U, Nicolay J, Valencak J, Stranzenbach R, Li N, Stadler R, Jonak C, Bauer W, Porkert S, Blaschke A, Meiß F, working group for cutaneous lymphoma of the Arbeitsgemeinschaft Dermatologische Forschung (ADF). Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. *J Eur Acad Dermatol Venereol* 2020

Nordmann T, Messerli-Odermatt O, Meier L, Micalletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiburger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. *Oncotarget* 2019; 10:6647-6650.

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krollik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Hartwig T, Schlapbach C, Conrad C, Flatz L, Dummer R, Navarini A, Cheng P, Yawalkar N, Schreiner B, Zwicky P, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. *Cell Rep* 2018; 25:3564-3572.e4.

Brüggen M, French L, Hoetzenecker W, Cozzio A, Dummer R, Desislava I, Chang Y, Schanz U, Haralambieva E, Kerl K, Guenova E. Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. *Acta Derm Venereol* 2018; 98:835-841.

Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018; 96:64-72.

Braun R, French L, Hafner J, Dummer R, Merat R, Arnold A, Gaide O, Hunger R, Ulrich K, Cozzio A. Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right Thing?. *Dermatology (Basel)* 2017

Trautinger F, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer M, Whittaker S, Willemze R, Pimpinelli N, Papadavid E, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C, Ortiz-Romero P, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. *Eur J Cancer* 2017; 77:57-74.

Guenova E, Hoetzenecker W, French L, Kazakov D, Dummer R, Mitev V, Navarini A, Saulite I, Mehra T, Contassot E, Chang Y, Desislava I, Cozzio A. Expression of CD164 on Malignant T cells in Sézary Syndrome. *Acta Derm Venereol* 2016; 96:464-7.

Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly* 2016; 146:w14279.

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. *J Immunother* 2016; 39:379-382.

Kleffel S, Hoetzenecker W, Cozzio A, Dummer R, Mihm M, Flaherty K, Frank M, Murphy G, Sharpe A, Kupper T, Thomi R, Lian C, Posch C, Barthel S, Mueller H, Schlapbach C, Guenova E, Elco C, Lee N, Juneja V, Zhan Q, Schatton T. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. *Cell* 2015; 162:1242-56.

Amann V, Cozzio A, Dummer R, Pascolo S, Kempf W, Kerl K, Kamarashev J, Desislava I, Dreier J, Guenova E. Disseminated Primary Cutaneous CD8+ Small/Medium-sized Pleomorphic T-cell Lymphoma Responding to Hydroxychloroquine. *Acta Derm Venereol* 2015; 95:602-3.

DeSimone J, Sodha P, Desislava I, Dummer R, Cozzio A, Guenova E. Recent advances in primary cutaneous T-cell lymphoma. *Curr Opin Oncol* 2015; 27:128-33.

Mehra T, Guenova E, French L, Dummer R, Hoetzenecker W, Haralambieva E, Schanz U, Nair G, Benz R, Moos R, Ikenberg K, Cozzio A. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. *JAMA Dermatol* 2015; 151:73-7.

Mehra T, Naumann A, Clasen S, Dummer R, Claussen C, Röcken M, Moos R, Guenova E, Mann S, Grözinger G, Garbe C. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. *PloS one* 2014; 9:e112535.

Rozati S, Kempf W, Ostheeren-Michaelis S, Bode-Lesniewska B, Zimmermann D, Dummer R, Cozzio A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. *J Clin Oncol* 2014; 34:e93-6.

Guenova E, Hoetzenecker W, Rozati S, Levesque M, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. *Expert Opin Investig Drugs* 2014; 23:457-67.

Kolios A, Marques Maggio E, Gubler C, Cozzio A, Dummer R, French L, Navarini A. Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. *Dermatology (Basel)* 2013; 226:302-10.

Dummer R, Rozati S, Guenova E, Cozzio A. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. *Future Oncol* 2013; 9:1061-4.

Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppli M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. *PloS one* 2013; 8:e53745.

Rozati S, Kerl K, Kempf W, Tinguely M, Zimmermann D, Dummer R, Cozzio A. Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. *J Cutan Pathol* 2012; 40:56-60.

Dummer R, Bernengo M, Cozzio A, Bagot M, Stadler R, Weichenthal M, Morris S, Whittaker S, Karrasch M, Hasan B, Becker J, Quaglino P, Knobler R. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. *J Clin Oncol* 2012; 30:4091-7.

Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. *Case Rep Oncol* 2012; 5:280-9.

Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncol Rep* 2012

Dummer R, Goldinger S, Cozzio A, French L, Karpova M. Cutaneous lymphomas: molecular pathways leading to new drugs. *J Invest Dermatol* 2011; 132:517-25.

Kempf W, Horwitz S, Prince H, Guitart J, Estrach T, Sanches J, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Berti E, Cerroni L, Pfaltz K, Vermeer M, Cozzio A, Ortiz-Romero P, Bagot M, Olsen E, Kim Y, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. *Blood* 2011; 118:4024-35.

Mangana J, Dziunycz P, Kerl K, Dummer R, Cozzio A. Prevalence of Merkel cell polyomavirus among Swiss Merkel cell carcinoma patients. *Dermatology (Basel)* 2010; 221:184-8.

Barysch M, Zaugg T, Schaffner R, Kreyden O, Hunger R, Brand C, Hrdlicka S, Kolm I, Cozzio A, Dummer R. Internet based health promotion campaign against skin cancer - Results of www.skincheck.ch in Switzerland. *Eur J Dermatol* 2009; 20:109-14.

Oberholzer P, Cozzio A, Dummer R, French L, Hofbauer G. Granulomatous slack skin responds to UVA1 phototherapy. *Dermatology (Basel)* 2009; 219:268-71.

Mangana J, Zipser M, Conrad C, Oberholzer P, Cozzio A, Knuth A, French L, Dummer R. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. *Eur J Dermatol* 2008; 18:566-70.

Golling P, Cozzio A, Dummer R, French L, Kempf W. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. *Leuk Lymphoma* 2008; 49:1094-103.

von Moos R, Lademann J, Lacouture M, Dummer R, Lorusso D, Scotte F, Sehouli J, Harrold K, Rayson D, Apro M, Thürlimann B, Hauschild A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. *EJO* 2008; 44:781-90.

Dummer R, Asagoe K, Cozzio A, Burg G, Doebbeling U, Golling P, Fujii K, Urošević M. Recent advances in cutaneous lymphomas. *J Dermatol Sci* 2007; 48:157-67.

Künzi V, Oberholzer P, Heinzerling L, Dummer R, Naim H. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. *The Journal of investigative dermatology* 2006; 126:2525-32.

Burg G, Nestle F, Schärer L, Michaelis S, Golling P, Feit J, Döbbling U, Cozzio A, Kempf W, Dummer R. Cutaneous malignant lymphomas: update 2006. *J Dtsch Dermatol Ges* 2006; 4:914-33.

Dummer R, Urosevic M, Cozzio A, Asagoe K, Döbbling U, Burg G. [Perspective of cutaneous lymphoma reserach]. *J Dtsch Dermatol Ges* 2006; 4:492-5.

Cozzio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, Schärer L, Burg G, Dummer R. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. *Leuk Lymphoma* 2006; 47:865-9.

Dummer R, Cozzio A, Urosevic M. Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?. *Exp Dermatol* 2006; 15:392-400.

Dummer R, Cozzio A, Meier S, Beyeler M, Laetsch B, Doebbeling U, Urosevic M. Standard and experimental therapy in cutaneous T-cell lymphomas. *J Cutan Pathol* 2006; 33 Suppl 1:52-7.

Burg G, Kurrer M, Knobler R, Meijer C, Pimpinelli N, Ralfkiaer E, Russell-Jones R, Sander C, Santucci M, Sterry W, Swerdlow S, Vermeer M, Wechsler J, Kerl H, Kazakov D, Kempf W, Cozzio A, Feit J, Willemze R, S Jaffe E, Dummer R, Berti E, Cerroni L, Chimenti S, Diaz-Perez J, Grange F, Harris N, Whittaker S. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. *J Cutan Pathol* 2005; 32:647-74.

Heinzerling L, Künzi V, Oberholzer P, Kündig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. *Blood* 2005; 106:2287-94.

Beyeler M, Hafner J, Beinder E, Fauchère J, Stöckli S, Fehr M, Dummer R. Special considerations for stage IV melanoma during pregnancy. *Archives of dermatology* 2005; 141:1077-9.

Urosevic M, Conrad C, Kamarashev J, Asagoe K, Cozzio A, Burg G, Dummer R. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. *Hum Pathol* 2005; 36:1020-4.

Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer P, Schultz J, Elzaouk L, Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. *Human gene therapy* 2005; 16:35-48.

Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, Nestle F, Dummer R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. *Arch Dermatol* 2004; 140:1490-5.

Heinzerling L, Dummer R, Pavlovic J, Schultz J, Burg G, Moelling K. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. *Experimental dermatology* 2002; 11:232-40.

Rochlitz C, Dietrich P, Herrmann R, Morant R, Heinzerling L, Escudier B, Baudin M, Acres B, Squiban P, Cavalli F, Jantschkeff P, Dreno B, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. *Cancer gene therapy* 2002; 9:289-95.

Heinzerling L, Dummer R, Burg G, Schmid-Grendelmeier P. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. *European journal of dermatology* : EJD 2002; 12:194-7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch